Seglentis (celecoxib and tramadol hydrochloride) tablets
Approval Date: Oct 2021
A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate
Belbuca® (buprenorphine) buccal film
Approval Date: Aug 2021
This is the first time a generic has been approved for Belbuca. For the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate
ZYNRELEF™ (BUPIVACAINE AND MELOXICAM) EXTENDED-RELEASE SOLUTION
Approval Date: May 2021
A combination of an amide local anesthetic and an NSAID for postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty
LYRICA® CR (PREGABALIN) EXTENDED-RELEASE TABLETS
Approval Date: Apr 2021
For the management of neuropathic pain associated with diabetic neuropathy; post-herpetic neuralgia. While previous generic versions of Lyrica have been approved in the past, this generic approval is for the Extended-Release tablets
HYSINGLA® ER (HYDROCODONE BITARTRATE) EXTENDED-RELEASE TABLETS
Approval Date: Mar 2021
For the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Posimir® (bupivacaine solution) for infiltration use
Approval Date: Feb 2021
Indicated for 72-hour post-surgical analgesia following shoulder surgery
Acetaminophen injection
Approval Date: Feb 2021
A new 500 mg dose indicated for the management of mild to moderate pain, or moderate to severe pain with adjudicative opioid analgesics
